Modality
Bispecific Ab
MOA
TYK2i
Target
IL-23
Pathway
Lipid Met
RCC
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
~Apr 2022
→ ~Jul 2023
Phase 3
~Oct 2023
→ ~Jan 2025
NDA/BLA
Apr 2025
→ Jun 2026
NDA/BLACurrent
NCT03018848
1,599 pts·RCC
2025-04→2026-06·Completed
1,599 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-152mo awayPh3 Readout· RCC
Trial Timeline
Q2Q3Q42026Q2
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-06-15 · 2mo away
RCC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03018848 | NDA/BLA | RCC | Completed | 1599 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Tezecilimab | Regeneron | Approved | IL-23 |